Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 10/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4219645 | 1.00 | GSR (0.41) | GSRCA2ALDH1A1MAPT | |
| SCHEMBL28921029 | 0.87 | — | — | |
| SCHEMBL8957333 | 0.87 | GSR (0.50) | GSRCA2ALDH1A1MAPT | |
| SCHEMBL14499693 | 0.77 | — | — | |
| SCHEMBL324551 | 0.77 | — | — | |
| SCHEMBL9019587 | 0.76 | GSR (0.41) | GSRCA2ALDH1A1MAPT | |
| SCHEMBL11060513 | 0.76 | GSR (0.41) | GSRCA2ALDH1A1MAPT | |
| SCHEMBL9019582 | 0.76 | GSR (0.41) | GSRCA2ALDH1A1MAPT | |
| SCHEMBL9019578 | 0.76 | GSR (0.38) | GSRCA2ALDH1A1MAPT | |
| SCHEMBL1774751 | 0.75 | GSR (0.54) | GSRCA2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270558-B1 | \"Compound for the treatment of atherosclerotic-thrombotic pathological conditions\ | CASAGRANDE CESARE (IT) | 2007-04-25 | — | — | EP | claimed |
| US-6525078-B1 | Compound for the treatment of atherosclerotic-thrombotic pathological conditions | CASAGRANDE CESARE (IT) | 2003-02-25 | — | — | US | claimed |
| EP-1270558-A1 | \"Compound for the treatment of atherosclerotic-thrombotic pathological conditions\ | Casagrande, Cesare (IT) | 2003-01-02 | — | — | EP | claimed |
| US-20090318432-A1 | Nitrate esters of aminoalcohols | SPEEDEL EXPERIMENTA AG (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-1270558-B1 | \"Compound for the treatment of atherosclerotic-thrombotic pathological conditions\ | CASAGRANDE CESARE (IT) | 2007-04-25 | — | — | EP | disclosed |
| US-6525078-B1 | Compound for the treatment of atherosclerotic-thrombotic pathological conditions | CASAGRANDE CESARE (IT) | 2003-02-25 | — | — | US | disclosed |
| EP-1270558-A1 | \"Compound for the treatment of atherosclerotic-thrombotic pathological conditions\ | Casagrande, Cesare (IT) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318432-A1 | Nitrate esters of aminoalcohols | NOS2, NOS1, NOS3 | GSR 354/4885CA2 2054/4885ALDH1A1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.